VLP Therapeutics – Imagine: Vaccines Without Borders

VLP Therapeutics

About VLP Therapeutics

vlptherapeutics.com

[News Release] VLP Therapeutics Japan, FUJIFILM sign contract manufacturing agreement for COVID-19 vaccine

2024-05-19T10:37:52-04:002020.10.01|

October 1, 2020 — VLP Therapeutics Japan, LLC (VLPTJ) announced on today that VLPTJ signed a contract manufacturing agreement with FUJIFILM Corporation (FUJIFILM) for a novel coronavirus (COVID-19) vaccine formulation developed by VLPTJ. This self-amplifying (replicon) RNA vaccine employs a platform technology proprietary to VLP Therapeutics, LLC, the US-based wholly owning parent company of VLPTJ.

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute

2018-05-10T22:27:03-04:002017.10.06|

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute Grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy October 6, 2017 Gaithersburg, MD – VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines announced today the receipt of a Phase I

Journal of Virology – 27 September 2017

2017-10-09T00:57:38-04:002017.09.27|

“Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design” Akane Urakamia, Mya Myat Ngwe Tunb, Meng Ling Moib, Atsuko Sakuraia, Momoko Ishikawaa, Sachiko Kunoa, Ryuji Uenoa, Kouichi Moritab and Wataru Akahata   http://jvi.asm.org/content/early/2017/09/21/JVI.01181-17.abstract

VLP Therapeutics Appoints Jacob Licht as Chief Operating Officer

2017-07-22T06:05:57-04:002017.07.21|

Gaithersburg, Md. — July 21, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer. Mr. Licht comes to VLP Therapeutics with nearly 20 years of business development and strategy experience

Clinical and Vaccine Immunology – July 2017, Volume 24, Issue 7

2017-10-09T00:57:52-04:002017.07.01|

“Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus” Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P. Zavala, Michael G. Rossmann, Sachiko Kuno,a Ryuji Ueno, Wataru Akahata http://cvi.asm.org/content/24/7/e00090-17.full.pdf+html

VLP Therapeutics Announces Convertible Note Investment from TomyK Ltd. for Accelerating Cancer Vaccine Development

2017-05-10T01:37:00-04:002017.05.09|

Gaithersburg, Md. — May 9, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it completed a convertible note financing with an angel investor Dr. Tomy Kamada, through his investment firm TomyK Ltd., that supports technology startups which

VLP Therapeutics Receives Notice of Allowance of Key U.S. composition of matter Patent for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP

2017-04-21T10:19:52-04:002017.04.19|

Patent covers a composition of matter for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP and method of use for cancer therapy Gaithersburg, Md. — April 19, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it successfully received a

VLP Therapeutics Appoints Danai Brooks, Managing Partner of Glen Echo Capital, to Advisory Board

2017-03-01T20:11:46-05:002017.03.01|

Gaithersburg, Md. — February 27, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that Danai Brooks, Managing Partner of Glen Echo Capital, has agreed to join VLP’s Advisory Board.  Mr. Brooks is an experienced biotechnology executive, having led

Go to Top